Platinib generic drug price and medication safety guide

Platinib (market name: Pujihua), as a highly efficient and specific inhibitor of the receptor tyrosine kinaseRET, has demonstrated excellent efficacy in the treatment of RET gene fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and RET-mutant medullary thyroid carcinoma (MTC). It effectively inhibits the growth of RET gene-mutated cells by blocking the phosphorylation of RET and its downstream molecules, bringing new treatment hope to patients with this type of cancer. Unfortunately, platinib has not yet been included in my country’s medical insurance catalog, and patients need to purchase it at their own expense.

Faced with the high price of the original platinib, many patients feel great financial pressure. Fortunately, the emergence of generic drugs provides patients with more affordable solutions. Take Lucius Pharmaceutical Company of Laos as an example. The generic version of Platinib produced by it is 100mg*120 tablets. The price is about more than 4,000 yuan, which is significantly lower than the original drug, which greatly reduces the financial burden of patients.

However, patients need to be extremely vigilant when purchasing and using generic drugs. You should choose to purchase through formal channels to ensure the quality and safety of medicines. At the same time, Platinib, as a prescription drug, must be used under the guidance of a doctor. Patients should consult a professional doctor in detail before use to understand the correct usage, dosage and potential adverse reactions of the drug in order to better manage the condition.

In addition, when using platinib, patients need to pay special attention to drug interactions, adverse reactions, and drug contraindications for special groups. Platinib may interact with other medications, affecting efficacy or increasing the risk of adverse reactions. Therefore, patients should truthfully inform their doctors about all the drugs they are taking, including prescription drugs, over-the-counter drugs, and health care products, before use. At the same time, platinib may cause adverse reactions such as hypertension, liver damage, and interstitial lung disease. Patients should pay close attention to their symptoms during use. If they feel unwell, they should seek medical treatment immediately and inform the doctor. For special groups such as pregnant women, lactating women, and those with liver and kidney dysfunction, special care must be taken when using platinib and strictly follow the doctor's instructions.

In short, platinib, as a highly effectiveRET inhibitor, provides a new treatment option for cancer patients with RET gene fusion-positive or mutated cancers. Although it is not yet included in medical insurance, with the introduction of generic drugs and the continuous improvement of medical insurance policies, patients will have more choices and less financial pressure when using platinib. However, during use, patients still need to pay close attention to drug interactions, adverse reactions and medication contraindications for special groups, and conduct regular monitoring and dosage adjustments under the guidance of a doctor to ensure the safety and effectiveness of treatment.